Radiology, Kameda Kyobashi Clinic, 3-1-1 Kyobashi Chuo Ward, Tokyo, 104-0031Japan; Breast Center, Kameda Medical Center, Kameda Medical Center, 929 Higashi-cho, Kamogawa City, Chiba, 296-8602, Japan.
Radiology, Kameda Kyobashi Clinic, 3-1-1 Kyobashi Chuo Ward, Tokyo, 104-0031Japan.
Acad Radiol. 2018 Aug;25(8):1003-1009. doi: 10.1016/j.acra.2018.01.015. Epub 2018 Mar 2.
We aimed to investigate the relationship between shear wave speed (SWS) of the lesion on preoperative breast ultrasonography (US) and disease-free survival of patients with primary operable invasive breast cancer.
This retrospective study was approved by our Institutional Review Board. The requirement for informed consent was waived. A total of 195 consecutive newly diagnosed invasive breast cancer patients (age 33-83 years; mean 54.0 years) with preoperative breast US with SWS measurement of the lesion were identified. They underwent surgery between May 2012 and May 2013. SWS was measured at the center and three marginal zones in the main tumors, and the maximum value was used for analyses. For 35 patients who underwent primary systemic therapy (PST), the maximum SWS before PST was used. Cox proportional hazards modeling was used to identify the relationship between clinical-pathologic factors and disease-free survival.
Fourteen recurrences occurred at 6-47 months (mean 22.3 months) after surgery. On multivariate analysis, a positive history of PST (hazard ratio [HR] = 4.93; 95% confidence interval [CI]: 1.66, 14.70; P = .004), adjuvant chemotherapy (HR = 3.67; 95% CI: 1.11, 12.1; P = .033), and higher maximum SWS (HR = 1.55; 95% CI: 1.07, 2.23; P = .020) were associated with poorer disease-free survival.
Higher maximum SWS on preoperative US, in addition to a positive history of PST and adjuvant chemotherapy, was significantly associated with poorer disease-free survival of patients with invasive breast cancer.
我们旨在研究术前乳腺超声（US）检测到的病变剪切波速度（SWS）与原发性可手术浸润性乳腺癌患者无病生存率之间的关系。
本回顾性研究获得了我院伦理委员会的批准，豁免了知情同意书的要求。共纳入了 195 例术前接受乳腺 US 并进行了病变 SWS 测量的新诊断为原发性可手术浸润性乳腺癌的连续患者（年龄 33-83 岁，平均 54.0 岁）。这些患者均于 2012 年 5 月至 2013 年 5 月间接受了手术治疗。在肿瘤的中心和三个边缘区域测量 SWS，并将最大值用于分析。对于 35 例接受了新辅助系统治疗（PST）的患者，使用 PST 前的最大 SWS 值。采用 Cox 比例风险模型确定临床病理因素与无病生存率之间的关系。
术后 6-47 个月（平均 22.3 个月）时发生了 14 例复发。多因素分析显示，PST 史阳性（风险比 [HR] = 4.93；95%置信区间 [CI]：1.66，14.70；P =.004）、辅助化疗（HR = 3.67；95% CI：1.11，12.1；P =.033）和较高的最大 SWS（HR = 1.55；95% CI：1.07，2.23；P =.020）与无病生存率较差相关。
术前 US 上的最大 SWS 以及 PST 史阳性和辅助化疗与浸润性乳腺癌患者的无病生存率较差显著相关。
